By using bispecific antibodies targeting a tumor-associated antigen (TAA) on the cancer cells, and CD3 on the T-cells, it is possible to redirect and activate any circulating T-cells against tumor cells independently of the specificity of their TCR. Thanks to the bridging action of such TAAxCD3 bsAb, T-cells are brought in close proximity of the target cancer cells, leading to subsequent T-cell activation and T-cell–mediated killing of the tumor cells.
For more information on T-cell redirecting κλ-bodies, please visit Light Chain Bioscience.
Read our latest news
Revolutionizing lipid droplet analysis: insights from Nanolive’s Smart Lipid Droplet Assay Application Note
Introducing the Smart Lipid Droplet Assay: A breakthrough in label-free lipid droplet analysis Discover the power of Nanolive's Smart Lipid Droplet Assay (SLDA), the first smart digital assay to provide a push-button solution for analyzing lipid droplet dynamics,...
The team of Professor Wojciech Chrzanowski in the Sydney Pharmacy School at the University of Sydney have published their findings on the toxic effect of titanium nanoparticles found in food. The paper “Impact of nano-titanium dioxide extracted from food products on...
2023 has been a record year for clients using the Nanolive system in their scientific publications. The number of peer-reviewed publications has continued to increase, and there has been a real growth in groups publishing pre-prints to give a preview of their work....
3D CELL EXPLORER
Budget-friendly, easy-to-use, compact solution for high quality non-invasive 4D live cell imaging
3D CELL EXPLORER-fluo
Multimodal Complete Solution: combine high quality non-invasive 4D live cell imaging with fluorescence